BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Precede Biosciences, a precision diagnostics and data company focused on enabling the next generation of precision medicines, today announced that it has ...
Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...
Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...
Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab ...
BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative ...
A new spinout from Dana-Farber Cancer Institute aims to deliver a series of blood tests aimed not only at directing patients to precision tumor treatments, but also at assisting drug developers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback